Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has closed on the second $10 million convertible note pursuant to a financing agreement entered in September, 2021, with Richard E. Uihlein, the Company’s Chairman and largest individual stockholder. In total, the Company has received $30 million in three convertible notes from Mr
Who to call at Galectin, and when
A new round usually means Galectin is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Galectin raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Galectin, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Galectin. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Galectin
Location
Norcross, Georgia, United States
About
The NAVIGATE trial (NAVIGATEnash.com), entitled “A Seamless Adaptive Phase 2b/3, Double-Blind, Randomized, Placebo-controlled Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis” began randomization of patients in August, 2020, and is posted on www.clinicaltrials.gov (NCT04365868). Galectin-3 has a significant role in cancer, and the Company has supported a Phase 1b study in combined immunotherapy of belapectin and KEYTRUDA in advanced melanoma and in head and neck cancer. This trial provided a strong rationale for moving forward into a Phase 2 development program which the company is considering.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Galectin raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
NorcrossBiotechnologyHealthcareHealth CareTherapeutics